Currently viewing the tag: "Alere"
On october 12th 2012 Alere was granted a USpatent on Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
as the abstract says :
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to […]
Uncertainty about consequences of the recent decision by the European Patent Organisation’s (EPO) Opposition Division (OD) on the NGAL patent Is the ruling really vital for BioPorto … and in case it is not – why is it not so ? While we are still (after 8 weeks) sitting waiting for the EPO – OD’s […]
Important highlight from Alere’s Q4 earnings session:
“Additionally, in January we launched our Cardiorenal panel in Europe, for use on the Triage platform. The Cardiorenal panel is the world’s first point of care test to combine BNP and NGAL to aid in the real-time assessment of cardiac and renal status. We believe this panel will […]
Stengaard 9:41 PM after looking rather carefully at Abbotts “statement” to EPO – I have to conclude – there is nothing new… its more or less the same arguments that was presented the last time they lost… Mr. FillandKill 10:01 PM https://register.epo.org/espacenet/appli… https://register.epo.org/espacenet/advan… Mr. FillandKill 10:05 PM The first link is […]
Is BioPorto trying to prevent usage of Alere’s Triage NGAL-test in its prime setting – the ER’s (Emergency Rooms) ?
As a consequence of the fact that EPO has declared they will issue the “Trauma patent” to Bioporto on the use of NGAL, an interesting question arises.
Will Bioporto use that patent to keep Alere/Biosite […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
